A review of randomized studies suggests that mineralocorticoid receptor antagonists further reduce proteinuria in patients with diabetes mellitus or non-diabetes mellitus causes of CKD when combined with renin-angiotensin system blockers (37). This evidence concerns the gene NR3C2 and chronic kidney disease.